May 15th 2024
The Food and Drug Administration approved Breyanzi for patients with pretreated, relapsed or refractory follicular lymphoma.
Phase 2 Interim Analysis Shows Improved Response in Patients with Follicular Lymphoma
August 12th 2020“These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments,” said Dr. John Tsai.
FDA Approves Tazverik for Certain Patients With Relapsed/Refractory Follicular Lymphoma
June 18th 2020The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.